Working to Eradicate Gynecologic Cancers

John K. Chan, MD

Regional Director of Gynecologic Oncology
California Pacific & Palo Alto Medical Foundation / Sutter Research Institute
3838 California Street
#410
San Francisco, CA
USA 94115

Papers:
9 Differences in presentation and survival of Asians versus Caucasians with ovarian cancer: a Gynecologic Oncology Group ancillary study of 7,914 patients 128 Disease stabilization vs. response after bevacizumab treatment in recurrent ovarian cancer: how do we determine clinical efficacy? 180 The increase in early detection and associated improved survival of cervical cancer in the US: a ten-year study of 6,414 patients 190 Trends in FDA approval of oncology drugs: have we made progress? 209 Correlation between type I uterine cancer and diet and lifestyle in US-born versus immigrant Asian subgroups 211 Types of surgery for morbidly obese endometrial cancer patients in the US: how and where do we make the largest impact? 212 Differences in survival between clear cell uterine and ovarian carcinoma patients 280 The increase in hospital charges associated with ovarian cancer treatment: an economic analysis of 83,552 patients 351 The use of electronic health record-based tools to improve cervical cancer screening compliance in a large community-based health care organization 385 Differences in BMI and physical activity in Whites vs. Asians in California in association with type I uterine cancer 411 The role of lymphadenectomy and radiation therapy for malignant mixed Müllerian uterine cancers A phase II evaluation of sunitinib (SU11248) in the treatment of persistent or recurrent clear cell ovarian carcinoma: an NRG oncology / gynecologic oncology group study